title: Comparative bioavailability of two sertraline tablet formulations after single-dose administration in healthy Thai volunteers.
abstract: OBJECTIVE
  To compare the bioavailability of two sertraline tablet (50 mg) formulations (Serlift from Ranbaxy Laboratories Ltd., Gurgaon Haryana, India, as a test formulation and Zoloft from Pfizer Australia Pty Ltd., West Ryde, New South Wales, Australia, as a reference formulation) in 24 healthy Thai male volunteers under fasting condition.
  
  
  METHODS
  A randomized, 2-treatment, 2-period, 2-sequence, single-dose, crossover study with a washout period of 3 weeks, was conducted in 24 healthy Thai male volunteers. Blood samples were collected at 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours following drug administration. Plasma concentrations of sertraline were determined using validated LC-MS/MS method. Noncompartmental pharmacokinetics and statistical analyses were performed using SAS software for Windows, release 9.1 (SAS Institute Inc., Cary, NC, USA).
  
  
  RESULTS
  The ratio of least square means and the 90% confidence intervals (CI) of the log-transformed data were 0.9950 (0.9111-1.0866) for Cmax, 1.0153 (0.9576-1.0764) for AUC(0-t) and 1.0110 (0.9510-1.0747) for AUC(0-infinity). In addition, the median tmax values for the test and reference formulations were similar (5.00 h). The 90% CI for Cmax, AUC(0-t) and AUC(0-infinity) were within the 0.8-1.25 interval of the US-FDA.
  
  
  CONCLUSIONS
  The test formulation (Serlift, Ranbaxy Laboratories Ltd., Gurgaon, Haryana, India) is bioequivalent to the reference formulation (Zoloft, Pfizer Australia Pty Ltd., West Ryde, New South Wales, Australia) both in terms of rate and extent of absorption after single-dose administration under fasting condition.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
authors.forename: W
authors.initials: W
authors.lastname: Tassaneeyakul
authors.forename: S
authors.initials: S
authors.lastname: Kanchanawat
authors.forename: D
authors.initials: D
authors.lastname: Gaysonsiri
authors.forename: S
authors.initials: S
authors.lastname: Vannaprasath
authors.forename: P
authors.initials: P
authors.lastname: Paupairoj
authors.forename: K
authors.initials: K
authors.lastname: Kittiwattanagul
authors.forename: S K
authors.initials: SK
authors.lastname: Tippabhotla
authors.forename: A
authors.initials: A
authors.lastname: Khuroo
authors.forename: B K
authors.initials: BK
authors.lastname: Panigrahy
authors.forename: S
authors.initials: S
authors.lastname: Reyar
authors.forename: T
authors.initials: T
authors.lastname: Monif
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D006207:Half-Life; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D020280:Sertraline / Q000097:blood / Q000493:pharmacokinetics*; D013785:Thailand
chemical_list: D000928:Antidepressive Agents; D020280:Sertraline